INTRODUCTION

Recombinant interferon-beta (rIFNβ)
‡ is currently the most common therapy for multiple sclerosis (MS). High dose, frequent administrations of rIFNβ have been shown in MS to inhibit progression to disability, reduce exacerbation rates, and decrease occurrence of new enhancing central nervous system (CNS) lesions as determined by magnetic resonance imaging (MRI) [1] [2] [3] [4] .
Administration of a recombinant protein is typically associated with peak and trough kinetics for inducing relatively high levels of neutralizing antibodies that predispose to decreased efficacy [6] .
In addition to induction of neutralizing antibodies [6] [7] [8] [9] [10] [11] , long term repeated injections of rIFNβ are associated with several clinically relevant side effects including depression, decreased production of red blood cells, leukocytes and platelets, as well as cellulitis and inflammation at sites of injection [12] . Moreover, liver toxicity possibly due to the sudden rise in serum levels of protein immediately after injection is also of great concern in patients undergoing long term rIFNβ therapy [7, 13] . As a result of the need for frequent dosing and the concurrent flu-like side effects that often occur following injection [14] , non-compliance in patients is common particularly during periods of disease stabilization [15] . Unfortunately for the non-compliant patient, intermittent rIFNβ dosage can result in subsequent increased disease activity [16] .
A single administration of the IFNβ gene offers the prospect of producing endogenous systemically distributed IFNβ protein over an extended period of time. The continuous protein synthesis and secretion characteristic of DNA-based delivery would eliminate the peak and trough kinetics characteristic of conventional rIFNβ injection regimens, thereby eliminating side effects and toxicity associated with bolus protein dosing. The dramatic reduction in dosing frequency possible with DNA-based delivery may also enhance patient acceptance and cost effectiveness of therapy.
Recently, intracranial injection of plasmid DNA-liposome complexes [17, 18] and intravenous injection of retrovirally transfected bone marrow cells [19] have been used to deliver the murine IFNβ gene in the CNS. Although these studies provide a proof of principle for IFNβ gene transfer for treating autoimmune demyelinating disease, approaches involving direct CNS delivery are unlikely to be practical in the clinical MS setting.
Given its relative abundance, accessibility, and mitotic stability, coupled with the ability to synthesize secreted proteins that are taken up into circulation, skeletal muscle provides the most [26, 27] .
Inhibition of EAE progression in mice following IFNβ β β β gene transfer. Our prior studies have
shown that treatment of SWXJ mice with s.c. injection of 10,000 IU/day rIFNβ over an eight week period starting on the day of EAE onset results in a significant inhibition of EAE progression [28, 29] .
To evaluate therapeutic effects of a gene-based therapy, we immunized eight week old female SWXJ with PLP 139-151 and randomized them on the day of EAE onset into four groups: 1) untreated mice;
2) mice treated in both anterior tibialis muscles with 10 µg pORF-null + EP; 3) mice treated in both anterior tibialis muscles with 10 µg pORF-murine IFNβ + EP; and 4) mice treated with 10,000 IU of rIFNβ injected s.c. every other day. Mice were weighed and evaluated daily for changes in neurologic signs over a period of 8 weeks after EAE onset and initiation of treatment. We found that compared to untreated mice, mice administered the pORF-murine IFNβ plasmid on the day of EAE onset and mice treated with rIFNβ every other day showed comparable clinical courses and highly significant inhibition of disease progression as determined by mean clinical scores over time (P<0.0001; Fig. 2 ).
Mice treated with the pORF-null plasmid showed no significant therapeutic effect when compared to untreated EAE mice.
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Decreased exacerbation rates in mice following IFNβ β β β gene transfer. In addition to inhibition of EAE progression, treatment of EAE with rIFNβ causes a significant decrease in exacerbation frequencies [28, 29] . To determine the relative impact on EAE exacerbation rates, the four groups of mice described above were evaluated for relapse frequencies over the last 6 weeks of the eight week observation period (i.e., following the initial acute attack). Exacerbations were assessed as an increase of at least one clinical score associated with at least a 7% decrease in body weight. Compared to untreated mice, the mean number of exacerbations per mouse (exacerbation rate) were significantly reduced in mice treated with pORF-murine IFNβ on the day of EAE onset and in mice treated with 10,000 IU of rIFNβ injected s.c. every other day (P<0.01; Fig. 3 ). Mice treated with the pORF-null plasmid showed no significant decrease in their exacerbation rate when compared to untreated EAE mice. Much of the success of our study may be attributed to the TriGrid TM EP technology (Ichor)
that provides an optimized electric field propagated at the site of DNA injection (Fig. 5A ). An EP device suitable for gene delivery into large animals and humans has been developed that provides automated control of integrated delivery of the DNA agent and the EP procedure (Fig. 5B ). This integrated injection/EP strategy provides spatial and temporal control of the injection process, thereby increasing the probability of high level vector uptake and gene expression and avoiding collateral damage to surrounding tissues. Coordinated injection and electric field propagation provide a convenient and effective way to achieve therapeutic levels of IFNβ using plasmid doses that compare favorably to those used in most other gene transfer protocols [22] . Thus, the efficiency of delivery and uptake may account for the observed long term elevation in splenic IFNβ biomarker activity consistent with prolonged expression and systemic circulation of IFNβ. This long term expression occurs even though the pORF-murine IFNβ contains CpG motifs often associated with early innate inflammatory responses at the sites of vector injection that can contribute to short term expression of 12 plasmid encoded genes [30] .
In our study, the splenic expression levels of three IFNβ inducible genes (2',5'-OAS, IFI56
and IRF7) 12 weeks after pORF-murine IFNβ delivery in healthy mice were significantly higher than those observed within the 24 hours following injection with rIFNβ protein (Fig. 1B) . Extended observations of 2',5'-OAS gene expression indicated that significant IFNβ bioactivity persisted for at least 18 weeks after a single EP mediated i.m. administration of the IFNβ gene (Fig. 1A) . This prolonged elevation of IFNβ activity was also evident eight weeks after treatment of EAE mice with pORF-murine IFNβ EP, in contrast to mice receiving rIFNβ every other day for eight weeks (Fig. 4) .
It should be noted that splenic levels of 2',5'-OAS levels were measured in EAE mice that were polymers that control vector release and activity [31] or modified 'latent' proteins that may be activated at sites of inflammation [32] . In addition, regulation may be achieved using orally administered bioactive molecules that control inducible promoters linked to murine IFNβ [33] [34] [35] or that mediate disaggregation and secretion of aggregated IFNβ trapped in endoplasmic reticulum [36] .
In addition, incorporation of "suicide genes" that produce prodruge mediated toxins or DNA crosslinking may provide a means to terminate plasmid gene expression even in non-dividing cells thereby offsetting unanticipated side effects that may emerge from long-term endogenous expression of IFNβ in muscle [37] .
Molecular Therapy, 2006 14 (3):416-422
13
Several of the well documented side effects of current rIFNβ delivery regimens are likely to be avoided with a gene-based therapeutic approach. The ability to provide long-term production of protein from a single administration would avoid the development of cellulitis and inflammation often occurring at sites of repeated rIFNβ protein injection [12] . Steady state production of IFNβ is also likely to minimize flu-like side effects associated with transient spikes in IFNβ after protein administration, which should reduce patient non-compliance that often leads to tapered rIFNβ dosage and subsequent increased disease activity [15, 16] . In addition, gene-based production of IFNβ also reduces the prospect of protein priming and subsequent development of neutralizing antibodies that predispose to decreasing biologic efficacy of rIFNβ injection therapy in MS [6] [7] [8] [9] [10] [11] . Finally, long term, gene based production of IFNβ is likely to provide a significant improvement in the cost effectiveness of therapy, since the relatively expensive process of recombinant protein manufacture is replaced by endogenous production. Thus, IFNβ gene transfer offers several advantages over current rIFNβ therapy and with the anticipation of improvements in second generation vectors, will likely provide a viable, effective, and appealing treatment alternative for MS and possibly for other chronic inflammatory disorders. the remainder of the study. All experiments were performed in a blinded manner. The blind was established and maintained throughout the course of experiments so that the investigator examining and clinically evaluating the mice was kept unaware of the treatment protocol used on each mouse throughout the experimental protocol. On the first day that clinical signs were detected, mice were incorporated randomly into different treatment protocol groups. As previously described [29] , relapse was assessed when mice showed an increase in observed neurologic disability of at least one clinical score unit sustained for at least 2 days coupled with an abrupt substantial loss in weight (≥7% weight loss). Exacerbation rate or relapse frequency was assessed as the mean number of clinical exacerbations per mouse in each treatment group. Mortality within 14 days of EAE onset was considered the result of the primary attack. Thus, mice dying within 14 days of disease onset as well as all relapses occurring prior to day 14 were not included in the determination of exacerbation rate.
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MATERIALS AND METHODS
Mice
Administration of Recombinant IFNβ β β β. Highly purified mouse IFNβ from E. coli expressing the murine IFNβ gene was purchased commercially (PBL Biomedical, Piscataway, NJ). The IFNβ was prepared fresh daily from frozen aliquots and was administered as previously described [29] under aseptic conditions on the day of EAE onset and every other day thereafter by s.c. injection of 10,000 IU (specific activity 3x10 7 IU/mg) in 0.1 ml of 0.01% mouse serum albumin in PBS. The dose of IFNβ selected represents approximately a 4-fold increase in effective dose/kg administered in human MS studies [1] . In a separate experiment, six Swiss Webster mice received four injections every other day of 10,000 IU IFNβ s.c. prior to euthanasia six hours (3 mice) and 24 hours (3 mice) after the last injection. Mice showed no apparent toxic side effects of any treatment protocols. 
